Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference CAMBRIDGE, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Sath Shukla, President and Chief Executive Officer of Spero Therapeutics, will participate in a fireside chat and be available for one-on-one meetings at the , to take place on Monday, May 20, 2024, at the NAS...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of NextEra Energy, Inc., Florida Power & Light Company, and NextEra Energy Capital Holdings, Inc. and other ratings that are associated with these issuers. The review was conducted through a rating committee held on 10 May 202...
Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update On track for topline data from SPR720 Phase 2a proof-of-concept trial in treatment-naive and treatment-experienced non-refractory NTM-PD patients, expected in 2H 2024Enrollment ongoing in PIVOT-PO, a pivotal Phase 3 clinical trial of oral tebipenem HBr in cUTIReceived FDA Fast Track designation for SPR206 for treatment of HABP/VABP due to CRABc and CRPACash balance of $82.3 million as of March 31, 2024; reiterate expected cash runway into late 2025 CAMBRIDGE, Mass., May 15, 2024 (GLOBE NEWSWI...
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024 Hemophilia Program: Ongoing registrational PRESent-2 and PRESent-3 studies of SerpinPC for the treatment of hemophilia B; PRESent-2 interim analysis planned in 2024Orexin Agonist Program: Cleared IND and initiated Phase 1 first-in-human clinical trial of ORX750, a highly potent and selective OX2R agonist for the treatment of narcolepsy; Clinical proof-of-concept data in acutely sleep-deprived healthy volunteers planned in 2H of 2024LockBody® Technology Platform: Ongoing Phase 1/2a study ...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 20,250 shares of its common stock to eleven newly-hired employees, with a grant date of May 6, 2024 (the "Grant Date"). The restricted stock units were granted pursua...
TELA Bio Reports First Quarter 2024 Financial Results MALVERN, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions today reported financial results for the first quarter ended March 31, 2024. Recent Highlights Reported revenue of $16.6 million in the first quarter, representing growth of 39% over the prior year period of 2023;Delivered the 13th consecutive quarter of at least 35% year-over-year growth;Increased demand for OviTex® and OviTex PRS Reinforced Tis...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.